MTA3抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P05917(MTA3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P05917(MTA3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The MTA3 (Metastasis-Associated Antigen 3) antibody is a tool used to detect the MTA3 protein, a member of the MTA family involved in epigenetic regulation. MTA3 is a component of the Mi-2/NuRD (Nucleosome Remodeling and Histone Deacetylation) complex, which plays a critical role in chromatin remodeling, gene silencing, and transcriptional regulation. Unlike other MTA family members (e.g., MTA1 and MTA2), MTA3 is primarily associated with estrogen receptor (ER)-signaling pathways and has been implicated in suppressing epithelial-to-mesenchymal transition (EMT), a key process in cancer metastasis.

Research highlights MTA3's dual role depending on cellular context. In ER-positive breast cancer, MTA3 acts as a tumor suppressor by repressing EMT and maintaining epithelial cell integrity. However, in other cancers, such as hepatocellular carcinoma or gastric cancer, elevated MTA3 expression may promote tumor progression. The MTA3 antibody is widely used in studies to analyze its expression patterns, interactions with chromatin modifiers, and regulatory mechanisms in both normal physiology and disease states. Its applications span Western blotting, immunohistochemistry, and immunofluorescence, aiding in the exploration of MTA3's role in cancer biology, developmental processes, and potential therapeutic targeting. Understanding MTA3 dynamics contributes to insights into epigenetic dysregulation in malignancies and strategies to modulate metastatic pathways.